Tilray Inc. ($TLRY) recently reported its fiscal 2026 results, marking a record revenue year with sales reaching approximately $915 million, an 11% increase from the prior year. Adjusted EBITDA rose 11% to $61.1 million, and adjusted net income nearly doubled to $12.2 million. Despite these gains, the company still posted a significant GAAP net loss of $49.6 million, which has tempered investor enthusiasm. While management projects adjusted EBITDA growth to between $68 million and $75 million for fiscal 2027, uncertainty remains about when Tilray will achieve consistent GAAP profitability. The company’s strategy now spans cannabis, alcoholic beverages, pharmaceutical distribution, and wellness products, with cannabis representing just 29% of total sales. This diversification, combined with ongoing share dilution from debt-for-equity swaps, has contributed to a cautious market response, leaving the stock down roughly 48% year-to-date despite recent modest rallies.
Latest Updates on Marijuana and CBD Stocks
Recent trading activity shows some positive momentum, with shares rising 6% on August 19 amid broader risk asset support following Treasury announcements that lowered long-term yields. However, Tilray’s stock performance continues to lag behind peers in the cannabis sector, highlighting company-specific challenges rather than sector-wide issues. The company’s international medical cannabis efforts, including new prescribing guidelines in Germany, and its expanding craft beer portfolio through BrewDog, underscore its shift toward a lifestyle and consumer packaged goods model rather than a pure cannabis play.
Insider buying also signals confidence at the management level, with CFO Carl Merton purchasing 10,000 shares at $4.62 in early August, increasing his stake to nearly 140,000 shares. This move contrasts with the broader market’s cautious stance and may reflect belief in Tilray’s long-term growth potential despite near-term hurdles.
Overall, Tilray is navigating a complex transition from a cannabis-focused company to a diversified consumer goods player. While hitting the $1 billion revenue milestone appears achievable, the market remains focused on profitability and the impact of dilution, factors that will likely continue to influence the stock’s performance in the near term.
Markets will resume tomorrow morning at 9:30 AM ET.
Did you know?
Stocks in the U.S. market have historically delivered an average annual return of about 10%, but this includes periods of significant ups and downs—highlighting the importance of long-term investing and patience.
Disclaimer
This content is for entertainment and discussion purposes only. It is based on publicly available headlines and social media commentary, which can be messy and ever-evolving. We are not financial advisors, and this is not investment advice. The publisher may hold positions in securities mentioned. We aim to keep things accurate—if you catch something off, please let us know.
Powered by - Trading Watch Premium
This data is 100% free and is made possible by our Monthly Supporters.
No Comments